SCHEMBL1630376

SCHEMBL1630376

O=C(Nc1ccc(-n2nccc2-c2ccc(O)cc2O)cc1)c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.54
NPC1 O15118 8/20 0.54
SMN1; SMN2 Q16637 7/20 0.54
TP53 P04637 4/20 0.54
ALDH1A1 P00352 3/20 0.54
MAPT P10636 2/20 0.54
GFER P55789 1/20 0.54
EPHX2 P34913 2/20 0.50
ROCK2 O75116 1/20 0.49
ROCK1 Q13464 1/20 0.49
GAA P10253 1/20 0.47
LMNA P02545 1/20 0.47
HIF1A Q16665 1/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP3A4 P08684 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631560 0.90 KCNK3 (0.52) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL1629510 0.89 TYR (0.48) RAB9ANPC1SMN1; SMN2TP53MAPT
SCHEMBL1629986 0.87 GAA (0.50) RAB9ASMN1; SMN2MAPTEPHX2GAA
SCHEMBL1629234 0.82 HDAC1 (0.50) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL1629945 0.81 NPC1 (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL1629168 0.80 MAPT (0.46) RAB9ANPC1ALDH1A1MAPTGFER
SCHEMBL1630445 0.79 POLB (0.48) RAB9ANPC1ALDH1A1MAPTKMT2A
SCHEMBL1628592 0.78 KCNK3 (0.49) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL1631466 0.77 ALDH1A1 (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL1630414 0.77 KDM4E (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP disclosed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US disclosed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US disclosed
EP-1776346-A1 1,5-DIPHENYLPYRAZOLES Merck Patent GmbH (DE) 2007-04-25 EP disclosed
WO-2006018082-A1 1,5-DIPHENYLPYRAZOLES MERCK PATENT GMBH (DE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085904-A1 1,5-Diphenylpyrazoles HSP90AB1, HSP90AA1, HSP90AB2P RAB9A 2251/4885NPC1 855/4885SMN1; SMN2 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.